2.要約四半期連結財務諸表及び主な注記
(1)要約四半期連結財政状態計算書
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2026年3月31日) | | 当第1四半期連結会計期間 (2026年6月30日) |
資産 | | | | | |
流動資産 | | | | | |
現金及び現金同等物 | | | 76,592 | | 72,699 |
営業債権及びその他の債権 | | | 46,157 | | 50,567 |
棚卸資産 | | | 51,595 | | 51,168 |
その他の金融資産 | | | 2,414 | | 2,425 |
その他の流動資産 | | | 6,326 | | 6,313 |
流動資産合計 | | | 183,086 | | 183,175 |
非流動資産 | | | | | |
有形固定資産 | | | 34,954 | | 35,216 |
無形資産 | | | 48,242 | | 49,970 |
使用権資産 | | | 2,588 | | 2,578 |
その他の金融資産 | | | 67,356 | | 64,143 |
繰延税金資産 | | | 6,957 | | 6,957 |
その他の非流動資産 | | | 3,172 | | 3,111 |
非流動資産合計 | | | 163,272 | | 161,978 |
資産合計 | | | 346,359 | | 345,153 |
| | | | | |
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2026年3月31日) | | 当第1四半期連結会計期間 (2026年6月30日) |
負債及び資本 | | | | | |
負債 | | | | | |
流動負債 | | | | | |
営業債務及びその他の債務 | | | 26,132 | | 24,956 |
その他の金融負債 | | | 273 | | 246 |
リース負債 | | | 913 | | 1,452 |
未払法人所得税 | | | 6,979 | | 2,850 |
その他の流動負債 | | | 7,806 | | 9,837 |
流動負債合計 | | | 42,105 | | 39,343 |
非流動負債 | | | | | |
その他の金融負債 | | | 235 | | 235 |
リース負債 | | | 1,654 | | 1,106 |
退職給付に係る負債 | | | 4,557 | | 4,158 |
繰延税金負債 | | | 5,875 | | 4,519 |
その他の非流動負債 | | | 59 | | 59 |
非流動負債合計 | | | 12,382 | | 10,079 |
負債合計 | | | 54,488 | | 49,423 |
資本 | | | | | |
資本金 | | | 5,174 | | 5,174 |
資本剰余金 | | | 4,547 | | 4,564 |
利益剰余金 | | | 246,691 | | 252,622 |
自己株式 | | | △2,440 | | △2,440 |
その他の資本の構成要素 | | | 37,578 | | 35,490 |
親会社の所有者に帰属する持分合計 | | | 291,551 | | 295,411 |
非支配持分 | | | 319 | | 318 |
資本合計 | | | 291,871 | | 295,730 |
負債及び資本合計 | | | 346,359 | | 345,153 |
E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2026-04-012026-06-30Q12027-03-312025-04-012025-06-302026-03-311falsefalsefalse451602026-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-04-012025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-04-012025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602026-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-03-31jpigp_cor:ShareCapitalIFRSMember451602026-03-31jpigp_cor:CapitalSurplusIFRSMember451602026-03-31jpigp_cor:RetainedEarningsIFRSMember451602026-03-31jpigp_cor:TreasurySharesIFRSMember451602026-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31451602026-03-31451602025-06-30451602026-04-012026-06-30451602026-06-30451602026-08-06451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-06-30451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602026-04-012026-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-04-012026-06-30jpigp_cor:ShareCapitalIFRSMember451602026-04-012026-06-30jpigp_cor:CapitalSurplusIFRSMember451602026-04-012026-06-30jpigp_cor:RetainedEarningsIFRSMember451602026-04-012026-06-30jpigp_cor:TreasurySharesIFRSMember451602026-04-012026-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-04-012026-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-04-012026-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-04-012026-06-30jpigp_cor:NonControllingInterestsIFRSMember451602026-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-06-30jpigp_cor:ShareCapitalIFRSMember451602026-06-30jpigp_cor:CapitalSurplusIFRSMember451602026-06-30jpigp_cor:RetainedEarningsIFRSMember451602026-06-30jpigp_cor:TreasurySharesIFRSMember451602026-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-06-30jpcrp_cor:ReportableSegmentsMember451602025-04-012025-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602025-04-012025-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-06-30jpcrp_cor:ReconcilingItemsMember451602026-04-012026-06-30jpcrp_cor:ReportableSegmentsMember451602026-04-012026-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602026-04-012026-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602026-04-012026-06-30jpcrp_cor:ReconcilingItemsMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure